Two dose levels of ifosfamide in malignant mesothelioma

Lung Cancer

Volumn 15, Issue 2, 1996, Pages 207-213

  Içli, Fikri ^a   Karaoǧuz, Handan ^a   Hastürk, Serap ^b   Kurt, Bahar ^b   Akbulut, Hakan ^a   Dinçol, Dilek ^a   Demirkazik, Ahmet ^a   Çay, Filiz ^a   Akyar, Serdar ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b Department of Thoracic Surgery   (Turkey)

Author keywords

Dose response; Ifosfamide; Malignant mesothelioma

Indexed keywords

IFOSFAMIDE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LUNG CANCER; MALE; MESOTHELIOMA; OCCUPATIONAL CANCER; PRIORITY JOURNAL;

EID: 0030249788     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(96)00584-3     Document Type: Article

References (13)

1. [1] Selçuk ZT, Çöplü L, Emri S, Kalyoncu AF, Şahin AA, Bariş YI. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey: analysis of 135 cases. Chest 1992; 102: 790-796.
2. [2] Krarup-Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 1991; 28: 319-330.
3. [3] Alberts AS, Falkson G, Van Zyl L. Malignant pleural mesothelioma: Phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 1988; 80: 698-700.
4. [4] Falkson G, Hunt M, Borden EC, Hayes JA, Falkson CI, Smith TJ. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992; 10: 337-343.
5. [5] Krarup-Hansen A, Martensson G, Hansen HH. Phase II trial of high dose ifosfamide (IFS) + mesna in malignant mesothelioma. Ann Oncol 1990; 1 Suppl: 57 (Abstr).
6. [6] Zidar BL, Metch B, Balcerzak SP, Pierce HI, Militello L, Keppen MD et al. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. Cancer 1992; 70: 2547-2551.
7. [7] Rusch VW. Diagnosis and treatment of pleural mesothelioma. Semin Surg Oncol 1990; 6: 279-285.
8. [8] Oken MM, Creech LH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
9. [9] World Health Organization. WHO Handbook for reporting results of cancer treatment. Offset publication no 48, 1979. Geneva, Switzerland: WHO.
10. [10] Cox DR. Analysis of binary data. London: Chapman and Hall, 1970.
11. [11] Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
12. [12] Cerny T, Leyvraz S, Dazzi H, Varini M, Kroner T, Marti C et al. Phase II trials of ifosfamide and mesna in advanced soft tissue sarcoma (STS) patients: a definite dose response relationship. Proc Am Soc Clin Oncol 1992; 11: 416 (Abstr 1462).
13. [13] Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 1993; 31 Suppl 2: 174-179.